March 25, 2024
Personal Information Protection Law (PIPL) was approved in China on August 20, 2021. It was the first comprehensive data protection legislation in the region. The Law entered into effect on November 1, 2021 and established personal information processing rules, data subject rights, and obligations for personal information processors, among other things. The PIPL aims to "protect the rights and interests of individuals", "regulate personal information processing activities" and "facilitate reasonable use of personal information".
Key provisions of the PIPL include:
The PIPL extends its territorial scope to the processing of personal information conducted outside of China, provided that the purpose of the processing is:
Moreover, the PIPL requires offshore "personal information processing entities" subject to the PIPL to establish a "dedicated office" or appoint a "designated representative" in China for personal information protection purpose.
Following the PIPL coming into effect, most organizations, especially those international companies who conduct business in China, have enthusiastically complied with the PIPL. However, most organizations will not have solutions associated with the data transfer mechanisms required by the PIPL, since data authorities in China have not officially released any guidance on the same to date.
The implementation of PIPL in China poses several challenges for organizations, including:
Overall, navigating the complexities of the PIPL and addressing its implementation challenges require careful planning, allocation of resources, and ongoing monitoring of regulatory developments to ensure compliance and mitigate risks associated with personal data processing in China.
As an organization, ProPharma has acted very quickly by engaging with external counsel to understand the PIPL laws that came into effect on November 1, 2021 and the GVP (Good Pharmacovigilance Practices) laws that came into effect on December 1, 2021.
Because a legal entity in China is a requirement under GVP, ProPharma is currently working toward the set up of a legal entity and we expect it to be in place by the end of March 2024.
Under PIPL, compliance is essential, particularly concerning the management of consent for cross-border personal data transfers. Our local Chinese entity plays a crucial role in aiding compliance efforts. By establishing an entity in China, ProPharma can effectively address data localization challenges and cater to data subjects' preferences regarding the transfer of their information.
Furthermore, leveraging our resources allows us to navigate the intricacies of PIPL seamlessly. From establishing robust consent management systems to ensuring compliance with oversight mechanisms, ProPharma is dedicated to assisting clients in meeting their PIPL obligations while maintaining operational efficiency and data security.
Navigating the complexities of PIPL implementation in China poses significant challenges for organizations, especially those conducting international business. ProPharma, with its proactive approach and expertise, stands ready to assist you in ensuring seamless compliance with the latest data protection laws.
Don't let PIPL implementation challenges hinder your operations. Contact ProPharma today for expert guidance, proactive solutions, and a streamlined path to compliance. Your data protection journey starts with us. Speak with an expert today!
TAGS: Medical Information Privacy PIPL China
August 5, 2024
As a rapidly expanding market, the Japan and Asia-Pacific (JAPAC) region presents a unique and complex landscape for those who are looking to establish a medical information (MI) function. Having a...
May 25, 2023
Our "Meet the Expert" series introduces you to our team of experts around the world. This "behind the curtain" view will help you get to know who we are on a professional and personal level, and...